GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Syncom Formulation (India) Ltd (NSE:SYNCOMF) » Definitions » Cyclically Adjusted Revenue per Share

Syncom Formulation (India) (NSE:SYNCOMF) Cyclically Adjusted Revenue per Share : ₹3.22 (As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Syncom Formulation (India) Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Syncom Formulation (India)'s adjusted revenue per share for the three months ended in Mar. 2024 was ₹0.900. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ₹3.22 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Syncom Formulation (India)'s average Cyclically Adjusted Revenue Growth Rate was -100.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2024-05-24), Syncom Formulation (India)'s current stock price is ₹13.00. Syncom Formulation (India)'s Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was ₹3.22. Syncom Formulation (India)'s Cyclically Adjusted PS Ratio of today is 4.04.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Syncom Formulation (India) was 5.12. The lowest was 1.92. And the median was 2.70.


Syncom Formulation (India) Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Syncom Formulation (India)'s Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Syncom Formulation (India) Cyclically Adjusted Revenue per Share Chart

Syncom Formulation (India) Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 3.09 3.22

Syncom Formulation (India) Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.09 3.14 3.17 3.22 3.22

Competitive Comparison of Syncom Formulation (India)'s Cyclically Adjusted Revenue per Share

For the Drug Manufacturers - Specialty & Generic subindustry, Syncom Formulation (India)'s Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Syncom Formulation (India)'s Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Syncom Formulation (India)'s Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Syncom Formulation (India)'s Cyclically Adjusted PS Ratio falls into.



Syncom Formulation (India) Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Syncom Formulation (India)'s adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.9/153.0345*153.0345
=0.900

Current CPI (Mar. 2024) = 153.0345.

Syncom Formulation (India) Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201312 0.591 91.425 0.989
201403 0.548 91.425 0.917
201406 0.414 94.103 0.673
201409 0.595 96.780 0.941
201412 0.609 96.780 0.963
201503 0.605 97.163 0.953
201506 0.534 99.841 0.819
201509 0.626 101.753 0.941
201512 0.519 102.901 0.772
201603 0.692 102.518 1.033
201606 0.516 105.961 0.745
201703 0.623 105.196 0.906
201706 0.608 107.109 0.869
201709 0.582 109.021 0.817
201712 0.683 109.404 0.955
201803 0.502 109.786 0.700
201806 0.422 111.317 0.580
201809 0.576 115.142 0.766
201812 0.625 115.142 0.831
201903 0.758 118.202 0.981
201906 0.690 120.880 0.874
201909 0.658 123.175 0.818
201912 0.598 126.235 0.725
202003 0.430 124.705 0.528
202006 0.394 127.000 0.475
202009 0.856 130.118 1.007
202012 1.092 130.889 1.277
202103 0.641 131.771 0.744
202106 0.665 134.084 0.759
202109 0.565 135.847 0.636
202112 0.690 138.161 0.764
202203 0.504 138.822 0.556
202206 0.547 142.347 0.588
202209 0.580 144.661 0.614
202212 0.831 145.763 0.872
202303 0.709 146.865 0.739
202306 0.637 150.280 0.649
202309 0.784 151.492 0.792
202312 0.837 152.924 0.838
202403 0.900 153.035 0.900

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Syncom Formulation (India)  (NSE:SYNCOMF) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Syncom Formulation (India)'s Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=13.00/3.22
=4.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Syncom Formulation (India) was 5.12. The lowest was 1.92. And the median was 2.70.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Syncom Formulation (India) Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Syncom Formulation (India)'s Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Syncom Formulation (India) (NSE:SYNCOMF) Business Description

Traded in Other Exchanges
Address
207, Saket Nagar, Near Saket Club, Indore, MP, IND, 452018
Syncom Formulation (India) Ltd is in the business of pharmaceuticals. The company operates through three segments including manufacturing and dealings in Pharmaceutical drugs and formulations, Trading of commodities, and Renting of property. It manufactures and markets pharmaceutical formulation products in various dosage forms like tablets, capsules, liquids orals, liquids vials, ampoule injections and dry vial injections, dry syrups, ointments, inhalers, and Herbals. The company's product includes generic, antiviral, antidepressant, cough suppressant, electrolyte, histamine, estrogen, and much more. It generates maximum revenue through the Pharmaceutical drugs and formulations segment.

Syncom Formulation (India) (NSE:SYNCOMF) Headlines

No Headlines